ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency.

Adenosine deaminase (ADA) deficiency is a disorder of the purine metabolism leading to combined immunodeficiency and systemic alterations, including skeletal abnormalities. We report that ADA deficiency in mice causes a specific bone phenotype characterized by alterations of structural properties and impaired mechanical competence. These alterations are the combined result of an imbalanced receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin axis, causing decreased osteoclastogenesis and an intrinsic defect of osteoblast function with subsequent low bone formation. In vitro, osteoblasts lacking ADA displayed an altered transcriptional profile and growth reduction. Furthermore, the bone marrow microenvironment of ADA-deficient mice showed a reduced capacity to support in vitro and in vivo hematopoiesis. Treatment of ADA-deficient neonatal mice with enzyme replacement therapy, bone marrow transplantation, or gene therapy resulted in full recovery of the altered bone parameters. Remarkably, untreated ADA-severe combined immunodeficiency patients showed a similar imbalance in RANKL/osteoprotegerin levels alongside severe growth retardation. Gene therapy with ADA-transduced hematopoietic stem cells increased serum RANKL levels and children's growth. Our results indicate that the ADA metabolism represents a crucial modulatory factor of bone cell activities and remodeling.

[1]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[2]  S. Galimberti,et al.  Long-Term Safety and Efficacy of Gene Therapyfor Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency , 2009 .

[3]  M. Trojanowska.  Role of PDGF in fibrotic diseases and systemic sclerosis. , 2008, Rheumatology.

[4]  E. Seeman,et al.  Structural basis of growth-related gain and age-related loss of bone strength , 2008, Rheumatology.

[5]  Yongwon Choi,et al.  Osteoimmunology: interactions of the bone and immune system. , 2008, Endocrine reviews.

[6]  Luca Biasco,et al.  Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. , 2007, The Journal of clinical investigation.

[7]  T. Suda,et al.  Maintenance of Quiescent Hematopoietic Stem Cells in the Osteoblastic Niche , 2007, Annals of the New York Academy of Sciences.

[8]  E. Laurenti,et al.  Dormant and Self‐Renewing Hematopoietic Stem Cells and Their Niches , 2007, Annals of the New York Academy of Sciences.

[9]  L. Notarangelo,et al.  Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). , 2007, Clinical immunology.

[10]  Wei-Ping Qian,et al.  B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. , 2007, Blood.

[11]  E. Vizi,et al.  Shaping of monocyte and macrophage function by adenosine receptors. , 2007, Pharmacology & therapeutics.

[12]  C. Carella,et al.  Imbalance of the Osteoprotegerin/RANKL Ratio in Bone Marrow Microenvironment After Allogeneic Hemopoietic Stem Cell Transplantation , 2006, Transplantation.

[13]  A. Villa,et al.  Osteopetroses and immunodeficiencies in humans , 2006, Current opinion in allergy and clinical immunology.

[14]  Won-Young Lee,et al.  Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. , 2006, Bone.

[15]  C. Di Serio,et al.  Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. , 2006, Blood.

[16]  G. Burnstock,et al.  Osteoblast responses to nucleotides increase during differentiation. , 2006, Bone.

[17]  L. Notarangelo,et al.  Bone marrow transplantation for severe combined immune deficiency. , 2006, JAMA.

[18]  C. Elford,et al.  Human Osteoblast Precursors Produce Extracellular Adenosine, Which Modulates Their Secretion of IL‐6 and Osteoprotegerin , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Kozo Nakamura,et al.  Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system , 2005, Immunological reviews.

[20]  J. Kunkel,et al.  Bone as an ion exchange organ: evidence for instantaneous cell-dependent calcium efflux from bone not due to resorption. , 2005, Bone.

[21]  S. Douglas,et al.  Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency scid) , 2005, Pediatric Radiology.

[22]  D. Rowe,et al.  Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. , 2004, Blood.

[23]  A. Bernad,et al.  Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support. , 2004, Blood.

[24]  Markus G. Manz,et al.  Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.

[25]  G. Chelimsky.  in children and adolescents , 2004 .

[26]  J. Aubin.  Regulation of Osteoblast Formation and Function , 2004, Reviews in Endocrine and Metabolic Disorders.

[27]  C. Saccone,et al.  Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target , 2003, Oncogene.

[28]  Alessandro Aiuti,et al.  Capillary electrophoresis in diagnosis and monitoring of adenosine deaminase deficiency. , 2003, Clinical chemistry.

[29]  D. Scadden,et al.  Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.

[30]  Haiyang Huang,et al.  Identification of the haematopoietic stem cell niche and control of the niche size , 2003, Nature.

[31]  V. Giusti,et al.  Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. , 2003, Diabetes.

[32]  A. Fischer,et al.  Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99 , 2003, The Lancet.

[33]  A. Aiuti.  Advances in gene therapy for ADA-deficient SCID. , 2002, Current opinion in molecular therapeutics.

[34]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[35]  F. Glorieux,et al.  Human fetal bone development: histomorphometric evaluation of the proximal femoral metaphysis. , 2002, Bone.

[36]  L. Notarangelo,et al.  Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement , 2002, Nature Medicine.

[37]  H. Frost,et al.  The "Muscle-Bone Unit" in Children and Adolescents , 2002, Calcified Tissue International.

[38]  G. Marotti,et al.  Bone as an ion exchange system: evidence for a link between mechanotransduction and metabolic needs. , 2002, American journal of physiology. Endocrinology and metabolism.

[39]  D. Scadden,et al.  Hematopoietic stem cell quiescence maintained by p21cip1/waf1. , 2000, Science.

[40]  D. Lacey,et al.  Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .

[41]  G. Rodan,et al.  Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. , 1999, Experimental cell research.

[42]  D. Lacey,et al.  Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. , 1999, Bone.

[43]  P A Hill,et al.  Bone Remodelling , 1998, British journal of orthodontics.

[44]  S. Shimegi.  Mitogenic Action of Adenosine on Osteoblast-Like Cells, MC3T3-E1 , 1998, Calcified Tissue International.

[45]  M. Blackburn,et al.  Adenosine Deaminase-deficient Mice Generated Using a Two-stage Genetic Engineering Strategy Exhibit a Combined Immunodeficiency* , 1998, The Journal of Biological Chemistry.

[46]  R. Winter,et al.  Short stature/short limb skeletal dysplasia with severe combined immunodeficiency and bowing of the femora: report of two patients and review. , 1991, Journal of medical genetics.

[47]  R. Wortmann,et al.  Basis for the chondro-osseous dysplasia associated with adenosine deaminase deficiency: selective toxicity to immature chondrocytes. , 1991, Advances in experimental medicine and biology.

[48]  D. Rimoin,et al.  Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. , 1985, The American journal of pathology.

[49]  P. Robey,et al.  Human bone cells in vitro. , 1985, Calcified tissue international.

[50]  R. Stern,et al.  Partial resolution of bone lesions. A child with severe combined immunodeficiency disease and adenosine deaminase deficiency after enzyme-replacement therapy. , 1980, American journal of diseases of children.

[51]  G. Vawter,et al.  Adenosine deaminase deficiency: frequency and comparative pathology in autosomally recessive severe combined immunodeficiency. , 1979, Clinical immunology and immunopathology.

[52]  I. Kaitila,et al.  The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiency. , 1976, The Journal of pediatrics.

[53]  I. Kaitila,et al.  Chondroosseous histopathology in adenosine deaminase deficient combined immunodeficiency disease. , 1976, Birth defects original article series.